Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.

The present invention relates to pharmaceutical dosage forms for oral administration comprising the drug substance 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile or any pharmaceutically acceptable salt thereof and to processes of making said solid pharmaceutical dosage forms.

The present invention discloses a rice bran sterol sugar-coated tablet comprising rice bran sterol, a filler and a coating agent, wherein a mass ratio of the rice bran sterol, the filler and the coating agent is 1:3.9-4.5:1.30-1.35. The filler is composed of starch, dextrin, talcum powder, calcium carbonate, microcrystalline cellulose, starch slurry, carboxymethyl starch sodium, magnesium stearate and silicon dioxide in a mass ratio of 1.29-1.5:0.5-0.71:1:1:0.24-0.25:1.86-2.25:0.16-0.18:0.028-0.03:0.14-0.17, and the coating agent is composed of white sugar, gum, gelatin, pigment and Chinese insect wax in a mass ratio of 201-249:5.56-8:1:0.06-0.07:1. The rice bran sterol sugar-coated tablet may be used for treating periodontitis and acute pharyngolaryngitis and has obvious treatment effects on peniculus system inflammations, and is harmless to the human body.

The present invention relates to nicotine-containing chewing gum compositions and the method of preparing the same. The present invention provides improved and stable nicotine-containing chewing gum compositions for use in nicotine replacement therapy, which provide rapid nicotine release in the oral cavity and effectively satisfy the craving that most smokers experience.

Oral dosage forms and granulations with a high loading of a methyl hydrogen fumarate prodrug are disclosed.

The oral cavity is an ideal-site for small molecule, nutrient and/or nutraceutical delivery to the systemic circulation due to the highly-vascularized, oral mucosa, near-neutral pH conditions, and avoidance of gastric and first-pass degradation. Accordingly, novel, saccharide-based, food-form, portable, individually wrapped, oral delivery systems that attach to these four, highly absorptive surfaces (e.g. gingival, buccal, soft palatal, sublingual) for a longer contact-duration than current orally available formulas resulting in greater, small molecule bioavailability, and a more rapid, therapeutic effect are preferred and described.

Compounds of formula (I), wherein A, R, W, Q, n, and m have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

##STR00001##

An enteric-coated pellet, a method for preparing the same and a formulation comprising the same are provided. The enteric-coated pellet can be an ilaprazole enteric-coated pellet.

Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.

The present invention relates to a compound of formula ##STR00001##
and to a pharmaceutically suitable acid addition salt thereof with a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1, for the treatment of certain CNS diseases.